# Nasdaq's Savage Split Showdown: CPOP, FTFT & GRTX!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-07-13T14:00:00.306Z
Source: https://newsyai.com/edition/68ef74da-59ad-46d6-94a4-9abdac107aac
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Nasdaq’s Reverse-Split Fuckery Reloads: CPOP, FTFT & GRTX Edition!** 

Futures mixed (Dow napping, Nasdaq still snorting AI/chip lines with that lingering Iran aftertaste), crude oil still flexing like a leveraged degen. July 4th bangs are dust, but the microcap meat grinder spins on under Nasdaq’s iron-fisted no-extra-cure rules—no mercy for repeat offenders. Yesterday’s limp is forgotten; today’s fresh splits hit the tape July 13 with savage ratios chasing that $1 bid-price hard-on. Bulls howl “compliance rocket + sector boner!” Bears screech “dilution gangbang, delisting graveyard!” Balls-deep into three brand-new volatility perverts.[[1]](https://finance.yahoo.com/calendar/splits/)

### 1) Pop Culture Group Co., Ltd. (CPOP): “1-for-10 Media Ape Stiffy vs. Offering Hangover & Volatility Rape”

**Why it’s loud**  
1-for-10 reverse split effective for trading July 13, 2026. Chinese digital entertainment/play-to-earn media play with retail apes chasing “post-split bounce + revenue growth narrative” after recent $8M offering; bears hammer the dilution track record, thin margins, and classic microcap pump-dump patterns.[[1]](https://finance.yahoo.com/calendar/splits/)

**Bull case (compliance cock rocket + content stiffy)**  
Sector tailwinds (digital media/entertainment) + split mechanics + low-float volume = parabolic rebound to $1–4+. Ape the listing save and ride the Kool-Aid streams!

**Bear case (dilution gangbang & split limp encore)**  
Serial compliance theater + governance/red-flag offerings + wafer-thin results = sub-$0.10 bust. Short the limp before the next capital raise or delisting notice!

**My take, first principles (real platform signal vs. capital-structure cancer)**  
Legitimate revenue growth in a hot niche provides short-term fuel, but extreme volatility, microcap scale, repeated offerings, and execution risks under stricter Nasdaq rules scream unsustainable structures. Real media hype with real dilution/token risk. Scalp the spunk? **$0.15–2.00**, **$0.60C** narrative pump—**P$0.08** fade.

### 2) Future FinTech Group Inc. (FTFT): “1-for-4 Fintech Narrative vs. Bid-Price Deficiency & Dilution Overhang”

**Why it’s loud**  
1-for-4 reverse split (new CUSIP too) effective July 13, 2026. Blockchain/fintech play with retail interest in “post-split recovery + tech narrative”; bears flag thin fundamentals, volatility history, and classic microcap traps.[[2]](https://www.nasdaq.com/press-release/future-fintech-group-announces-reverse-stock-split-2026-07-08)

**Bull case (compliance cock rocket + blockchain stiffy)**  
Sector tailwinds (fintech/crypto-adjacent) + split mechanics + volume = $1–3+ rebound. Ape the momentum stiffy!

**Bear case (delisting rape & burn limp)**  
Thin results + governance/execution ghosts + ratio creep + dilution track record = sub-$0.20 crash. Short the limp before the next notice!

**My take, first principles (real ops signal vs. listing cancer)**  
Genuine compliance mechanics offer short-term breathing room in a volatile low-float environment, but microcap scale, execution risks, and dilution overhang under tighter rules highlight a classic trap. Real fintech hype with real downside risk. Scalp the spunk? **$0.20–1.50**, **$0.55C** retail pump—**P$0.10** fade.

### 3) Galera Therapeutics Inc. (GRTX): “1-for-200 Biotech Nuclear Split vs. Cash Burn & Compliance Theater”

**Why it’s loud**  
Extreme 1-for-200 reverse split effective July 13, 2026. Biotech play (radiation protection/cancer focus) with retail apes chasing “post-split bounce + pipeline narrative”; bears hammer the nuclear ratio, cash burn, governance risks, and delisting ghosts under new rules.[[1]](https://finance.yahoo.com/calendar/splits/)

**Bull case (compliance cock rocket + science stiffy)**  
Sector tailwinds (biotech/oncology) + split mechanics + low-float volume = parabolic rebound to $1–5+. Ape the listing save and grow the clinical Kool-Aid!

**Bear case (dilution rape & repeat-split limp encore)**  
Serial compliance theater + massive dilution history + wafer-thin clinical results = sub-$0.05 wipeout. Short the limp before the next offering or delisting notice!

**My take, first principles (real science signal vs. capital-structure cancer)**  
Legitimate bid-price fix buys short-term breathing room in a hot low-float environment, but the nuclear ratio creep, fresh dilution overhang, cash burn, and execution risks under stricter Nasdaq rules scream unsustainable structures. Real biotech hype with real token/dilution risk. Scalp the spunk? **$0.05–1.20**, **$0.30C** narrative pump—**P$0.03** fade.

**Tape-Side Tactics (CPOP Media Squeeze, FTFT Fintech Grab & GRTX Biotech Nuke – July 13 Edition)**  
- **CPOP**: **$0.15–2.00** content stiffy; **$0.60C** narrative pump, **P$0.08** dilution fade.  
- **FTFT**: **$0.20–1.50** fintech stiffy; **$0.55C** retail pump, **P$0.10** fade.  
- **GRTX**: **$0.05–1.20** science stiffy; **$0.30C** momentum pump, **P$0.03** dilution fade.  

New split rules tightening the screws amid crude cock-up and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions!

**Sources** (for tracking every claim above):  
- Reverse splits & reactions: Yahoo Finance Stock Splits Calendar, NasdaqTrader, GlobeNewswire, PR Newswire (July 2026 data).  
- Nasdaq reverse-split rule changes & compliance: Company filings and exchange alerts (2025-2026 updates).  
- Broader microcap/premarket context & volatility: Yahoo Finance, recent company announcements (June-July 2026).  
- Company specifics via recent filings, offerings, and exchange alerts.
